Researchers at the National Institutes of Health and international partners have identified the hormone GDF15 as the primary cause of severe morning sickness. The study reveals that a woman’s sensitivity to the hormone, influenced by her pre-pregnancy exposure levels, determines the severity of symptoms during gestation.
TLDR: Scientists have linked the hormone GDF15 to hyperemesis gravidarum, a debilitating form of pregnancy sickness. By understanding how pre-pregnancy hormone levels influence sensitivity, researchers are developing new strategies to prevent and treat severe nausea, potentially transforming prenatal care for millions of women worldwide.
Researchers at the National Institutes of Health (NIH), in collaboration with the University of Cambridge and the University of Southern California, have identified a specific hormone as the primary driver of nausea and vomiting during pregnancy. The study, published in the journal Nature, pinpoints the protein GDF15 as the chemical signal responsible for both standard morning sickness and its most severe form, hyperemesis gravidarum. This condition can lead to profound dehydration, weight loss, and hospitalization, yet its biological cause remained elusive for decades, often dismissed as a psychological or purely behavioral issue.
The research team discovered that the fetus produces GDF15 in the placenta, which then circulates in the mother’s bloodstream and binds to specialized receptors in the brainstem. These receptors are located in the area postrema, a region known as the “vomiting center” of the brain. The study found that the severity of a woman’s symptoms is directly linked to her sensitivity to this hormone. This sensitivity is largely determined by the levels of GDF15 she was exposed to prior to becoming pregnant, creating a biological threshold for nausea.
Data from over 18,000 participants revealed that women with naturally lower levels of GDF15 in their blood before conception are significantly more likely to experience severe sickness when the fetus begins producing the hormone. Conversely, women with higher pre-pregnancy levels—often due to a rare genetic variant or underlying health conditions like thalassemia—appear to be desensitized to the hormone’s effects. This suggests that the body can build a tolerance to GDF15, a finding that has immediate implications for preventative medicine and prenatal planning.
To test this hypothesis, the researchers conducted experiments in animal models. They found that mice exposed to high doses of GDF15 experienced a significant loss of appetite, which serves as a common proxy for nausea in laboratory settings. However, mice that were pre-treated with a low dose of the hormone before receiving a larger surge did not show the same symptoms. This confirms that prior exposure provides a protective effect against the sudden hormonal spike associated with the first trimester of pregnancy, effectively “priming” the brain to ignore the signal.
The identification of GDF15 also clarifies the role of a specific genetic mutation in the GDF15 gene. While it might seem counterintuitive, women carrying a mutation that leads to lower circulating levels of the hormone are at a much higher risk for hyperemesis gravidarum. Because their neurological systems are unaccustomed to the protein, the rapid increase during pregnancy overwhelms their receptors. This genetic insight allows clinicians to identify high-risk patients long before they conceive, potentially allowing for early intervention strategies.
This breakthrough shifts the focus of prenatal care from reactive symptom management to targeted biological intervention. Current treatments for severe morning sickness, such as anti-emetics, are often ineffective for the most severe cases or carry concerns regarding fetal safety. By targeting the GDF15 pathway, scientists hope to develop therapies that either block the hormone’s access to the brain or safely increase a woman’s hormone levels before pregnancy to build immunity.
Future clinical trials will likely investigate the safety and efficacy of metformin, a drug known to increase GDF15 levels, as a potential pre-conception treatment for those at high risk. Additionally, researchers are exploring the use of monoclonal antibodies to block GDF15 receptors in the brain for women already experiencing severe symptoms. These advancements represent a major step forward in understanding a condition that affects millions of people but has historically been under-researched and dismissed by the broader medical community.
Susan Carter serves as a Senior Correspondent for Just Right News, where she leads the network’s comprehensive coverage of Health, Medicine, and Public Policy. With a career dedicated to dissecting the complexities of the American healthcare system, Susan brings a principled perspective to the most pressing debates of the day. Her reporting is characterized by a commitment to individual liberty, fiscal responsibility, and a healthy skepticism of government overreach, making her a vital voice for audiences seeking clarity in an increasingly regulated landscape.
Raised in Minneapolis, Minnesota, Susan’s professional outlook is deeply informed by the values of the American heartland. Growing up in the Twin Cities, she witnessed firsthand the importance of community-driven solutions and the resilience of the individual. This Midwestern foundation instilled in her a firm belief that the best answers to public policy challenges often come from local innovation and personal responsibility rather than top-down federal mandates. Her background allows her to translate complex legislative jargon into stories that resonate with families who value common sense and local autonomy.
Now based in Baltimore, Maryland, Susan operates from a unique vantage point at the intersection of medical innovation and urban policy. Living and working in a city renowned for its world-class medical institutions and significant public health challenges, she has a front-row seat to the realities of the modern healthcare landscape. Her proximity to these hubs of research and policy allows her to scrutinize how government intervention affects the quality of care and the freedom of medical professionals. In Baltimore, she sees the tangible results of policy decisions, using the city as a lens through which to examine the broader national health debate and the impact of federal spending on local communities.
As the lead for the acclaimed feature series “The Cost of Care,” Susan dives deep into the economic realities facing patients and providers alike. Her work focuses on the necessity of price transparency, the benefits of market competition, and the preservation of the sacred doctor-patient relationship. She is a staunch advocate for the idea that a well-informed public is the best defense against bureaucratic inefficiency. Through this series, she has exposed the hidden drivers of rising medical expenses, always seeking to empower the individual consumer over the massive institution.
Susan’s reporting on public policy is characterized by a commitment to rigorous inquiry and a focus on constitutional limits. Whether she is analyzing new pharmaceutical regulations, investigating the impact of federal health mandates, or exploring the future of medical technology, her goal remains the same: to provide Just Right News audiences with the facts they need to navigate a complex world. By blending her Midwestern sensibilities with the insights gained from her base in Maryland, Susan Carter has become a trusted authority for those who believe that personal freedom and public health are inextricably linked. Her work continues to challenge the status quo, advocating for a system that respects the taxpayer and prioritizes the patient.